The earnings call presented a mixed outlook. While there was significant progress in the FDA review and commercial readiness for Anaphylm, the company faced substantial revenue declines and increased losses. The anticipation of Anaphylm's market entry and strategic preparations provide optimism, but financial challenges persist.

Company Guidance -

Q2 2025

During the Aquestive Therapeutics First Quarter 2025 Earnings Conference Call, the company provided several key metrics and guidance for the upcoming periods. Dan Barber, CEO, highlighted that they are in the commercial prelaunch phase for Anaphylm, with an FDA action date anticipated in late January or early February of 2026. The company has prepared for the launch by attending 25 conferences and publishing 16 posters and manuscripts, expecting nearly 30 by the FDA action date. In regards to financials, total revenues decreased by 28% to $8.7 million compared to the first quarter of 2024, primarily due to a decrease in manufacturer and supply revenue. The net loss for the quarter was $22.9 million, and the company revised its full-year 2025 revenue guidance to $44 million to $50 million, with a non-GAAP adjusted EBITDA loss of $47 million to $51 million. The company plans to de-emphasize AQST-108 studies to free up capital for Anaphylm's launch, aiming for a fast start in 2026 if the FDA approves the product.

Anaphylm FDA Review Progress

Aquestive is over a month into FDA review for Anaphylm Epinephrine Sublingual film. An FDA action date is anticipated for late January or early February of 2026.

Commercial Prelaunch Phase for Anaphylm

Aquestive has officially entered the commercial prelaunch phase for Anaphylm, focusing on assembling a marketing team with significant experience, including members who built EpiPen to a billion-dollar brand.

Increased Awareness Efforts

The company has attended 25 conferences and published 16 posters and manuscripts, with plans to reach 30 publications by the FDA action date.

Strategic Payer Engagement

Aquestive is leveraging existing distribution and payer contracts to prepare for Anaphylm's launch, aiming to save months of startup time.

Aquestive Therapeutics (AQST) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AQST Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-0.17 / -	-0.03	―	―	―
May 12, 2025	2025 (Q1)	-0.17 / -0.24	-0.17	-41.18% (-0.07)
Mar 05, 2025	2024 (Q4)	-0.13 / -0.19	-0.12	-58.33% (-0.07)
Nov 04, 2024	2024 (Q3)	-0.12 / -0.13	-0.03	-333.33% (-0.10)
Aug 06, 2024	2024 (Q2)	-0.12 / -0.03	-0.1	70.00% (+0.07)
May 07, 2024	2024 (Q1)	-0.09 / -0.17	0.11	-254.55% (-0.28)
Mar 05, 2024	2023 (Q4)	-0.09 / -0.12	-0.23	47.83% (+0.11)
Nov 06, 2023	2023 (Q3)	-0.11 / -0.03	-0.23	86.96% (+0.20)
Aug 07, 2023	2023 (Q2)	-0.12 / -0.10	-0.36	72.22% (+0.26)
May 02, 2023	2023 (Q1)	-0.14 / 0.11	-0.32	134.38% (+0.43)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AQST Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 12, 2025	$2.85	$2.29	-19.65%
Mar 05, 2025	$2.79	$2.58	-7.53%
Nov 04, 2024	$5.15	$4.76	-7.57%
Aug 06, 2024	$3.40	$3.43	+0.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aquestive Therapeutics (AQST) report earnings?

Aquestive Therapeutics (AQST) is schdueled to report earning on Aug 12, 2025, After Close (Confirmed).

What is Aquestive Therapeutics (AQST) earnings time?

Aquestive Therapeutics (AQST) earnings time is at Aug 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AQST EPS forecast?

AQST EPS forecast for the fiscal quarter 2025 (Q2) is -0.17.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing